Clinical Trial Update: Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial comparing dostarlimab alone vs cobolimab plus dostarlimab in melanoma is currently active but not recruiting. The study includes melan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Cobolimab (cobolimab)
• Dostarlimab (Jemperli) (dostarlimab)

Snippet

Sponsor: Diwakar Davar | Conditions: Melanoma Stage III, Melanoma Stage IV | Phase 2 | Status: ACTIVE_NOT_RECRUITING